Gossamer Bio receives Nasdaq bid-price deficiency notice; deadline March 2025

Gossamer Bio, Inc.

Nasdaq notified Gossamer Bio that its stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Sept 10, 2024.
Company has 180 calendar days, until March 10, 2025, to regain compliance by closing at $1.00 for at least 10 consecutive business days.
If not compliant by March 2025, may transfer to Nasdaq Capital Market for an additional 180-day cure period, subject to other standards.
Company may consider options such as a reverse stock split but cannot guarantee it will regain compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.